BillionToOne, Inc.

NASDAQ:BLLN

Medical - Diagnostics & Research

Healthcare
$91.54 +0.84%

+$0.84 today

Market cap
$4.37B
Beta
0.90
P/E (TTM)
182.6
EPS (TTM)
$0.55
52W Low $61.96High $138.70

Volume 1.44M

Average 0.59M

BLLN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

BillionToOne, Inc.NASDAQ: BLLN

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 190.3% from a year ago

Cash & equivalents stood at $548.63M at the end of Q2 FY2026, up 190.3% from a year earlier and up 2.1% from the prior quarter.

Context

  • Cash & equivalents amounted to 75.2% of total assets at the end of Q2 FY2026, up 14.7 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +190.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$548.63M+2.1% QoQ
Last fiscal yearDec 2025
$495.98M+159.0% YoY
Year agoJun 2025
$188.96M+190.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+190.3%——
1 year+159.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
495.98M USD
Year-over-year change
+159.0%
2-year CAGR
+125.8%

Cash & Equivalents vs competitors

How BLLN compares with its peers on the latest reported figures

  • BLLN's Jun 2026 cash & equivalents of $548.63M is the 3rd highest of the 9 companies compared; the peer median is $134.97M.
  • Its year-over-year change of +190.3% is the highest of 9, against a peer median of +1.6%.
  • Cash & equivalents amounts to 75.2% of total assets for BLLN, versus a peer median of 15.5%.
BLLN Competitors Peer median
Cash & Equivalents for BLLN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NTRANatera, Inc.Jun 2026$1.09B +9.1%+32.2%41.1%
GHGuardant Health, Inc.Sep 2026$1.03B +77.0%+38.7%54.5%
BLLNBillionToOne, Inc.Jun 2026$548.63M +190.3%—75.2%
VCYTVeracyte, Inc.Jun 2026$299.52M +36.5%+33.0%20.2%
NEONeoGenomics, Inc.Jun 2026$145.54M -5.9%-15.4%10.8%
MYGNMyriad Genetics, Inc.Mar 2026$124.4M +35.5%+38.0%18.5%
WGSGeneDx Holdings Corp.Jun 2026$60.32M -18.6%-8.6%12.5%
GRALGRAIL, Inc.Jun 2026$55.65M -56.3%+1.1%2.0%
FLGTFulgent Genetics, Inc.Mar 2026$23.4M -65.2%-14.2%2.0%
Peer median (excluding BLLN) $134.97M+1.6%+16.6%15.5%

Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents97.27M191.48M495.98M
Short-term Investments000
Net Receivables9.09M24.71M41.62M
Inventory7.2M8.73M17.55M
Other Current Assets1.94M2.9M5.42M
Total Current Assets115.5M227.82M560.56M
Property, Plant & Equipment (Net)73.87M68.85M67.1M
Goodwill000
Intangible Assets000
Long-term Investments000
Tax Assets000
Other Non-current Assets2.31M5.39M4.99M
Total Non-current Assets76.18M74.24M72.1M
Total Assets191.68M302.06M632.65M
Account Payables3.21M4.3M7.18M
Short-term Debt53.75M6.22M5.6M
Tax Payables000
Deferred Revenue3.02M2.81M2.19M
Other Current Liabilities4.26M6.64M20.44M
Total Current Liabilities66.8M28.39M47.96M
Long-term Debt35M51.48M57.23M
Deferred Tax Liabilities000
Deferred Revenue (Non-current)001.29M
Other Non-current Liabilities1.8M2.76M0
Total Non-current Liabilities94.4M105.92M104.59M
Total Liabilities161.2M134.31M152.55M
Common Stock000
Retained Earnings(240.63M)(282.2M)(274.75M)
Accumulated OCI000
Other Stockholders Equity00(1.79M)
Minority Interest000
Total Equity30.47M167.75M480.11M
Total Debt146.35M109.38M108.9M
Net Debt49.08M(82.1M)(387.08M)

BillionToOne, Inc.

NASDAQ:BLLN

Intrinsic Alpha fair value

Locked

Current Price

$91.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.